Table 3. Challenges for new serological tests for NCC diagnosis.

Test	Challenges
Antibody test	Identify antigens or epitopes to maintain high sensitivity and specificity compared to native antigens.
	Increase the sensitivity for single brain lesion.
	Identify antigens capable to differentiate exposure from infection.
	Identify antigens capable to differentiate viable and non-viable cysticercosis.
	Produce these antigens or epitopes in recombinant or synthetic way to have an easier and reproducible source of antigen.
	Use these antigens or epitopes to develop a point of care test, to have a primary tool in field settings.
Antigen test	Produce MoAbs or nanobodies against T. solium metacestodes in order to increase sensitivity and specificity.
	Standardize a qualitative assay with a better reproducibility and repeatability.
	Produce a test capable of differentiating viable and non-viable cysticercosis, with a high PPV for extraparenchymal NCC.
	Assay needs to perform well in urine samples to avoid invasive and risky sampling methods.
	Develop a point of care test, to have a primary tool in field settings.

Note: NCC, neurocysticercosis.